Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Kantonsspital St. Gallen, St. Gallen, Switzerland.

Survival: monthsCountry:Switzerland
Toxiciy Grade:4City/State/Province:St. Gallen
Treatments:Biologic therapyHospital:Kantonsspital St. Gallen
Drugs:Journal:Link
Date:Mar 2010

Description:

Patients:
This phase II study involved 45 hepatocellular carcinoma patients who had not received prior systemic treatment. The median age was 63 years and 87% were male.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The highest reported toxicity level was grade 4 and included fatigue and anemia. The most common adverse events were anemia (grade 1-4), thrombocytopenia (grades 1-3), and fatigue (grade 1-4).

Results:
The median overall survival was 9.3 months.

Support:
This study was supported by Pfizer, Inc., makers of sunitinib (trade name: SUTENT).

Correspondence: Dr. Dieter Koeberle; email: [email protected]



Back